Justin Chakma - 25 Nov 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Chief Business Officer
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
25 Nov 2024
Net transactions value
-$1,411,742
Form type
4
Filing time
27 Nov 2024, 16:11:54 UTC
Previous filing
04 Jan 2024
Next filing
04 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Sale $459,422 -32,814 -14% $14.00 203,566 25 Nov 2024 Direct F1
transaction SPRY Common Stock Sale $592,570 -42,186 -21% $14.05 161,380 26 Nov 2024 Direct F2
transaction SPRY Common Stock Sale $359,750 -25,000 -15% $14.39 136,380 27 Nov 2024 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average sale price for the transaction reported was $14.0008, and the range of prices were between $14.00 and $14.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F2 The weighted average sale price for the transaction reported was $14.0466, and the range of prices were between $13.95 and $14.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.